Drug
CBL-514 clinical trials
Also written CBL-514.
- studies test it
- 14
- open now
- 5
- in phase 3
- 3
- first study started
- 2018
Keep track of what changes. Save the CBL-514 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
13 studies that test it; most in 2026 (4); 1 more planned to start later
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 2 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 1 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 10
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 0
Caliway Biopharmaceuticals Co., Ltd. (14)
Studies
Open first, then newest update. How each study uses CBL-514 is read from its arms, and is right about nine times in ten.
Testing it · 14
- A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )Not yet recruitingPhase 3Caliway Biopharmaceuticals Co., Ltd.NCT07526974Written as CBL-514 Injection
- A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous FatNot yet recruitingPhase 2Caliway Biopharmaceuticals Co., Ltd.NCT07608757Written as CBL-514 Injection
- A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous FatRecruitingPhase 2Caliway Biopharmaceuticals Co., Ltd.NCT07608770Written as CBL-514 Injection
- A Study to Evaluate the Maintenance of Efficacy and Long-term Safety of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)Not yet recruitingPhase 3Caliway Biopharmaceuticals Co., Ltd.NCT07733947Written as CBL-514 Injection
- A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous FatRecruitingPhase 3Caliway Biopharmaceuticals Co., Ltd.NCT07140939Written as CBL-514 Injection
- A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease LipomasCompletedPhase 2Caliway Biopharmaceuticals Co., Ltd.NCT06303570Written as CBL-514 injection
- A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2)CompletedPhase 2Caliway Biopharmaceuticals Co., Ltd.NCT05836779Written as CBL-514 injection
- A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy VolunteersCompletedPhase 2Caliway Biopharmaceuticals Co., Ltd.NCT05234736Written as CBL-514
- A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.CompletedPhase 2Caliway Biopharmaceuticals Co., Ltd.NCT06005441Written as CBL-514 injection
- A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)CompletedPhase 2Caliway Biopharmaceuticals Co., Ltd.NCT04575467Written as CBL-514
- A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous FatCompletedPhase 2Caliway Biopharmaceuticals Co., Ltd.NCT05736107Written as CBL-514 Injection
- A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)CompletedPhase 2Caliway Biopharmaceuticals Co., Ltd.NCT04897412Written as CBL-514 Injection
- A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous FatCompletedPhase 2Caliway Biopharmaceuticals Co., Ltd.NCT04698642Written as CBL-514
- A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy VolunteersCompletedPhase 1Caliway Biopharmaceuticals Co., Ltd.NCT04699669Written as CBL-514